List of investigational sleep drugs

This is a list of investigational sleep drugs, or drugs for the treatment of sleep disorders that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

GABAA receptor potentiators

 * EVT-201 – GABAA receptor positive allosteric modulator
 * Lorediplon (GF-015535-00) – GABAA receptor positive allosteric modulator
 * Zuranolone (SAGE-217) – GABAA receptor positive allosteric modulator

Orexin receptor antagonists

 * Seltorexant (MIN-202, JNJ,42847922, JNJ-922) – selective OX2 receptor antagonist
 * Vornorexant (ORN-0829, TS-142) – dual OX1 and OX2 receptor antagonist

Melatonin receptor agonists

 * Piromelatine (Neu-P11) – melatonin receptor agonist and 5-HT1A and 5-HT1D receptor agonist

Nociceptin receptor agonists

 * Sunobinop (IMB-115, IT-1315, S-117957, V-117957) – nociceptin receptor agonist

Orexin receptor agonists

 * Danavorexton (TAK-925) – OX2 receptor-selective agonist via IV infusion
 * TAK-994 – OX2 receptor agonist pill (orally available)

Monoaminergics

 * Flecainide/modafinil (THN-102) – modafinil (dopamine reuptake inhibitor) and flecainide (antiarrhythmic) combination
 * Mazindol controlled release (NLS-1001, NLS-1) – norepinephrine-predominant serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI)
 * Reboxetine (AXS-12) – norepinephrine reuptake inhibitor (NRI)

GABAA receptor inhibitors

 * Pentylenetetrazole (BTD-001) – GABAA receptor negative allosteric modulator